Home » Vivaldi Buys Flu Vaccine R&D Assets from Baxter
Vivaldi Buys Flu Vaccine R&D Assets from Baxter
Vivaldi Biosciencies has acquired R&D assets for live attenuated influenza vaccines; this includes intellectual property, clinical data and materials.
Genetic Engineering & Biotechnology News
Genetic Engineering & Biotechnology News
Upcoming Events
-
23Apr
-
25Apr
-
07May
-
14May
-
30May